Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 4
Submit an article Journal homepage
87
Views
27
CrossRef citations to date
0
Altmetric
Short Communication

Maintenance Therapy with a Monthly Injection of Alemtuzumab Prolongs Response Duration in Patients with Refractory B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (B-CLL/SLL)

Catherine Thieblemont Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, FranceCorrespondence[email protected]
,
Fadhela Bouafia Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
,
Emmanuel hornez Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
,
Charles Dumontet Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
,
Sophie Tartas Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
,
Daciana Antal Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
,
Bernard Lemieux Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
,
Catherine Traullé Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
,
Daniel Espinouse Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
,
Gilles Salles Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
&
Bertrand Coiffier Hematology Departement, Hospices civils de Lyon, Claude Bernard University, 69 495 Pierre-Benite, France
 show all
Pages 711-714 | Received 10 Aug 2003, Published online: 03 Aug 2009

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Eric van den Neste, Rémi Letestu, Thérèse Aurran-Schleinitz, Loïc Ysebaert, Pierre Feugier, Stéphane Leprêtre & Caroline Dartigeas. (2012) Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?. Leukemia & Lymphoma 53:3, pages 362-370.
Read now
Tamar Tadmor. (2011) Alemtuzumab (Campath-1H) for chronic lymphocytic leukemia: a drug in search of its optimal schedule. Leukemia & Lymphoma 52:10, pages 1831-1833.
Read now
Raimundo Fernando Bezares, German Stemelin, Alicia Diaz, Daniel Argentieri, Emilio Lanari Zubiaur, Guy Garay, Miguel Bartomioli, Ricardo Ryser & Gustavo Milone. (2011) Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis. Leukemia & Lymphoma 52:10, pages 1936-1941.
Read now

Articles from other publishers (24)

Anne Bordron, Cristina Bagacean, Adrian Tempescul, Christian Berthou, Eléonore Bettacchioli, Sophie Hillion & Yves Renaudineau. (2019) Complement System: a Neglected Pathway in Immunotherapy. Clinical Reviews in Allergy & Immunology 58:2, pages 155-171.
Crossref
Andrew C. Cannon & Fausto R. LoberizaJr.Jr.. (2015) Review of Antibody-Based Immunotherapy in the Treatment of Non-Hodgkin Lymphoma and Patterns of Use. Clinical Lymphoma Myeloma and Leukemia 15:3, pages 129-138.
Crossref
Pau AbrisquetaNeus VillamorMaría José TerolEva González-BarcaMarcos GonzálezChristelle FerràEugenia AbellaJulio DelgadoJose A. García-MarcoYolanda GonzálezFelix CarbonellSecundino FerrerEncarna MonzóIsidro JarqueAna MuntañolaMireia ConstantsLourdes Escoda, Xavier CalvoSabela BobilloJosé Bruno Montoro, Emili MontserratFrancesc Bosch. (2013) Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood 122:24, pages 3951-3959.
Crossref
Michael A. Fridrik & Alexander Egle. (2013) The role of maintenance strategies in lymphoma and CLL
. memo - Magazine of European Medical Oncology 6:2, pages 102-108.
Crossref
Jeremy L. Warner & Jon E. Arnason. (2012) Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Therapeutic Advances in Hematology 3:6, pages 375-389.
Crossref
Matthew S. Kaufman, Angelica Caramanica, Dale Janson, Nancy Driscoll, Christina Johnson, Nina Kohn, Tarun Wasil & Kanti R. Rai. (2010) Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. Medical Oncology 28:2, pages 532-538.
Crossref
Xavier C. Badoux, Michael J. Keating & William G. Wierda. (2010) What is the Best Frontline Therapy for Patients with CLL and 17p Deletion?. Current Hematologic Malignancy Reports 6:1, pages 36-46.
Crossref
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy and Radiopharmaceuticals 26:1, pages 1-64.
Crossref
Elaine M. SloandMatthew J. OlnesAarthie ShenoyBarbara WeinsteinCarol BossKelsey LoeligerColin O. WuKenneth MoreA. John BarrettPhillip ScheinbergNeal S. Young. (2010) Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions. Journal of Clinical Oncology 28:35, pages 5166-5173.
Crossref
Michael Fiegl & Jiri Mayer. 2010. Methods of Cancer Diagnosis, Therapy, and Prognosis. Methods of Cancer Diagnosis, Therapy, and Prognosis 343 358 .
Davide Rossi & Gianluca Gaidano. (2009) Richter syndrome: molecular insights and clinical perspectives. Hematological Oncology 27:1, pages 1-10.
Crossref
Robert O. Dillman. 2009. Principles of Cancer Biotherapy. Principles of Cancer Biotherapy 303 406 .
Peter Hillmen, Aleksander B. Skotnicki, Tadeusz Robak, Branimir Jaksic, Anna Dmoszynska, Jingyang Wu, Cynthia Sirard & Jiri Mayer. (2007) Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 25:35, pages 5616-5623.
Crossref
A C Rawstron, N Villamor, M Ritgen, S Böttcher, P Ghia, J L Zehnder, G Lozanski, D Colomer, C Moreno, M Geuna, P A S Evans, Y Natkunam, S E Coutre, E D Avery, L Z Rassenti, T J Kipps, F Caligaris-Cappio, M Kneba, J C Byrd, M J Hallek, E Montserrat & P Hillmen. (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21:5, pages 956-964.
Crossref
Danelle F JamesThomas J Kipps. (2007) Alemtuzumab in chronic lymphocytic leukemia. Future Oncology 3:1, pages 29-42.
Crossref
Thomas Fietz & Eckhard Thiel. 2007. Targeted Therapies in Cancer. Targeted Therapies in Cancer 153 163 .
A C Rawstron, R de Tute, A S Jack & P Hillmen. (2006) Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia 20:12, pages 2102-2110.
Crossref
Kanti R. Rai. (2006) Novel Therapeutic Strategies With Alemtuzumab for Chronic Lymphocytic Leukemia. Seminars in Oncology 33, pages 15-22.
Crossref
S Faderl, S Coutré, J C Byrd, C Dearden, A Denes, M J S Dyer, S A Gregory, J G Gribben, P Hillmen, M Keating, S Rosen, P Venugopal & K Rai. (2005) The evolving role of Alemtuzumab in management of patients with CLL. Leukemia 19:12, pages 2147-2152.
Crossref
Amanda L. Cox, Sara A. J. Thompson, Joanne L. Jones, Vicki H. Robertson, Geoff Hale, Herman Waldmann, D. Alastair S. Compston & Alasdair J. Coles. (2005) Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. European Journal of Immunology 35:11, pages 3332-3342.
Crossref
William G. Wierda, Thomas J. Kipps & Michael J. Keating. (2005) Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 23:26, pages 6325-6332.
Crossref
Janice MY Brown. (2005) Exogenous administration of immunomodulatory therapies in hematopoietic cell transplantation: an infectious diseases perspective. Current Opinion in Infectious Diseases 18:4, pages 352-358.
Crossref
P P Piccaluga, G Martinelli, M Malagola, M Rondoni, F Bonifazi, G Bandini, G Visani & M Baccarani. (2004) Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. Leukemia 19:1, pages 135-135.
Crossref
. (2004) Current Awareness in Hematological Oncology. Hematological Oncology 22:2, pages 73-84.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.